Search

Your search keyword '"Martin-Martinez, M. A."' showing total 84 results
Start Over Author "Martin-Martinez, M. A."
84 results on '"Martin-Martinez, M. A."'

6. Structure sensitivity reaction of chloroform hydrodechlorination to light olefins using Pd catalysts supported on carbon nanotubes and carbon nanofibers

Author

Agencia Estatal de Investigación (España), Ministerio de Ciencia e Innovación (España), Comunidad de Madrid, Liu, S., Fernandez-Ruiz, C., Iglesias Juez, Ana, Martin-Martinez, M., Bedia, J., Marini, C., Agostini, G., José Rodriguez, J., María Gómez-Sainero, L., Agencia Estatal de Investigación (España), Ministerio de Ciencia e Innovación (España), Comunidad de Madrid, Liu, S., Fernandez-Ruiz, C., Iglesias Juez, Ana, Martin-Martinez, M., Bedia, J., Marini, C., Agostini, G., José Rodriguez, J., and María Gómez-Sainero, L.

Abstract

The upgrading of wasted chloroform in hydrodechlorination for the production of olefins such as ethylene and propylene is studied by employing four catalysts (PdCl/CNT, PdCl/CNF, PdN/CNT, and PdN/CNF) prepared by different precursors (PdCl2 and Pd(NO3)2) supported on carbon nanotubes (CNT) or carbon nanofibers (CNF). TEM and EXAFS-XANES results confirm that Pd nanoparticle size increases in the order: PdCl/CNT < PdCl/CNF ∼ PdN/CNT < PdN/CNF, descending the electron density of Pd nanoparticles in the same order. It illustrates that PdCl-based catalysts show donation of electrons from support to Pd nanoparticles, which is not observed in PdN-based catalysts. Moreover, this effect is more evident in CNT. The smallest and well-dispersed Pd nanoparticles (NPs) on PdCl/CNT with high electron density favor an excellent and stable activity and a remarkable selectivity to olefins. In contrast, the other three catalysts show lower selectivity to olefins and lower activities which suffer strong deactivation due to the formation of Pd carbides on their larger Pd nanoparticles with lower electron density, compared to PdCl/CNT. © 2023 The Authors

Published
2023

15. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study

Author

Pun, B. T., Badenes, R., Heras La Calle, G., Orun, O. M., Chen, W., Raman, R., Simpson, B. -G. K., Wilson-Linville, S., Hinojal Olmedillo, B., Vallejo de la Cueva, A., van der Jagt, M., Navarro Casado, R., Leal Sanz, P., Orhun, G., Ferrer Gomez, C., Nunez Vazquez, K., Pineiro Otero, P., Taccone, F. S., Gallego Curto, E., Caricato, Anselmo, Woien, H., Lacave, G., O'Neal, H. R., Peterson, S. J., Brummel, N. E., Girard, T. D., Ely, E. W., Pandharipande, P. P., Creteur, J., Bogossian, E. G., Peluso, L., Gonzalez-Seguel, F., Hidalgo-Calibin, V., Carreno-Montenegro, P., Rojas, V., Tobar, E., Ramirez-Palma, A., Herrera-Davis, K., Ferre, A., Legriel, S., Godet, T., Fraisse, U., Goncalves, B., Mazeraud, A., Tzimou, M., Rasulo, F., Beretta, S., Marchesi, M., Robba, C., Battaglini, D., Pelosi, P., Mazzeo, A. T., Noto, A., Servillo, G., Marra, A., Cutuli, S. L., Pintaudi, G., Stival, Eleonora, Tanzarella, E. S., Roman-Pognuz, E., Concetta Massaro, C. M., Elhadi, M., Smit, L., Olasveengen, T., Pereira, I. J., Teixeira, C. M., Santos, A., Valente, Marianna, Granja, C., Pereia, R., Silva, J., Furquet, B., Garcia Simon, M., Godoy Torres, D. A., Monleon, B., Morcillo, E., Romero, N., Serrano, Alessia, Torrico Sanchez, S., Perez Caballero, F. L., Pena Luna, I., Baeza Gomez, I., Calizaya Vargas, M., Morillas Perez, J., Carrasco Gomez, G., Molina Latorre, R., Moya Gutierrez, S., Baron Barrera, I. P., Delgado Palacios, C., Garcia Gongora, B., Labrador Romero, L., Galarza, L., Catalan-Monzon, I., Rodriguez-Martinez, E., Murcia Gubianas, C., Belles, A., Rodriguez Delgado, M. E., Caballero, J., Morales, D., Pujol, A., Rubio, J., Alvarez Torres, E., Carvajal Revuelta, E., de la Calle Gil, I., Fernandez Tomas, B., Gallego Rodriguez, B., Gonzalez Serrano, M., LaTorre Andreu, P., Perez Lucendo, A., Abril Palomares, E., Gonzalez Gonzalez, E., Martin Delgado, M. C., Munoz De Cabo, C., Aznar, P. T., Calvo, C. A., Garutti, I., Higuero, F., Martinez-Gascuena, D., Maseda, E., Insausti, I., Montero Feijoo, A., Suarez-de-la-Rica, A., Del Moral Barbudo, B., Garcia Blanco-Traba, Y., Gimenez Santamarina, M. C., Gonzalo Millan, A., Llorente Damas, S., Pestana Lagunas, D., Reyes Garcia, I., Ruiz Perea, A., Ortega Guerrero, A., Marmol Cubillo, M. J., Diaz Munoz, D., Garcia de Castrillon i Ramal, S., Andorra Sunyer, X., Noci Moreno, M. D. L. N., Perez Manrique, R. M., del Campo Molina, E., Martinez Quintana, M. E., Fernandez-Gonzalo, S., Goma Fernandez, G., Navarra-Ventura, G., Baro Serra, A., Fuster, C., Plans Galvan, O., Gil-Castillejos, D., Dalorzo Gonzalez, M., Moran Gallego, F. J., Paredes Borrachero, I., Rodriguez Villamizar, P., Romeu Prieto, J., Sanchez Carretero, M. J., Gallardo Sanchez, S., Bustos Molina, F., Garcia Perez, M. L., Castello-Mora, P., Puig, J., Sanchis-Martin, M. R., Sanchis-Veryser, C. A., Vicente-Fernandez, M. P., Zaragoza, R., Lizama, L., Torres, I., Alvarez, C., Ramirez, P., Martin Cerezuela, M., Montero, M. J., Garcia Cantos, J., Valls, P., Aretxabala Cortajarena, N., Garcia Domelo, P., Gonzalez Cubillo, L., Martin Martinez, M., Perez Francisco, I., Poveda Hernandez, Y., Quintano Rodero, A., Rodriguez Nunez, C., Siegemund, M., Estermann, A., Zellweger, N., Ben Saida, I., Boussarsar, M., Esen, F., Ergin Ozcan, P., Berkey, C., Harb, C., Tandy, M. H., Morgan, E., Shephard, K., Hyzy, R. C., Kenes, M., Nelson, K., Hosse, R. E., Vance, K. M., Austin, C. A., Lerner, A., Sanders, E., Balk, R. A., Bennett, D. A., Vogel, A. R., Chowdhury, L., Devulapally, K., Woodham, M., Cohen, S., Patel, N., Kuza, C. M., Sing, M., Roberson, S., Drumright, K., Sehgal, S., Lahue, S. C., Douglas, V. C., Sarwal, A., Caricato A. (ORCID:0000-0001-5929-120X), Stival E., Valente M., Serrano A. (ORCID:0000-0002-7622-0101), Pun, B. T., Badenes, R., Heras La Calle, G., Orun, O. M., Chen, W., Raman, R., Simpson, B. -G. K., Wilson-Linville, S., Hinojal Olmedillo, B., Vallejo de la Cueva, A., van der Jagt, M., Navarro Casado, R., Leal Sanz, P., Orhun, G., Ferrer Gomez, C., Nunez Vazquez, K., Pineiro Otero, P., Taccone, F. S., Gallego Curto, E., Caricato, Anselmo, Woien, H., Lacave, G., O'Neal, H. R., Peterson, S. J., Brummel, N. E., Girard, T. D., Ely, E. W., Pandharipande, P. P., Creteur, J., Bogossian, E. G., Peluso, L., Gonzalez-Seguel, F., Hidalgo-Calibin, V., Carreno-Montenegro, P., Rojas, V., Tobar, E., Ramirez-Palma, A., Herrera-Davis, K., Ferre, A., Legriel, S., Godet, T., Fraisse, U., Goncalves, B., Mazeraud, A., Tzimou, M., Rasulo, F., Beretta, S., Marchesi, M., Robba, C., Battaglini, D., Pelosi, P., Mazzeo, A. T., Noto, A., Servillo, G., Marra, A., Cutuli, S. L., Pintaudi, G., Stival, Eleonora, Tanzarella, E. S., Roman-Pognuz, E., Concetta Massaro, C. M., Elhadi, M., Smit, L., Olasveengen, T., Pereira, I. J., Teixeira, C. M., Santos, A., Valente, Marianna, Granja, C., Pereia, R., Silva, J., Furquet, B., Garcia Simon, M., Godoy Torres, D. A., Monleon, B., Morcillo, E., Romero, N., Serrano, Alessia, Torrico Sanchez, S., Perez Caballero, F. L., Pena Luna, I., Baeza Gomez, I., Calizaya Vargas, M., Morillas Perez, J., Carrasco Gomez, G., Molina Latorre, R., Moya Gutierrez, S., Baron Barrera, I. P., Delgado Palacios, C., Garcia Gongora, B., Labrador Romero, L., Galarza, L., Catalan-Monzon, I., Rodriguez-Martinez, E., Murcia Gubianas, C., Belles, A., Rodriguez Delgado, M. E., Caballero, J., Morales, D., Pujol, A., Rubio, J., Alvarez Torres, E., Carvajal Revuelta, E., de la Calle Gil, I., Fernandez Tomas, B., Gallego Rodriguez, B., Gonzalez Serrano, M., LaTorre Andreu, P., Perez Lucendo, A., Abril Palomares, E., Gonzalez Gonzalez, E., Martin Delgado, M. C., Munoz De Cabo, C., Aznar, P. T., Calvo, C. A., Garutti, I., Higuero, F., Martinez-Gascuena, D., Maseda, E., Insausti, I., Montero Feijoo, A., Suarez-de-la-Rica, A., Del Moral Barbudo, B., Garcia Blanco-Traba, Y., Gimenez Santamarina, M. C., Gonzalo Millan, A., Llorente Damas, S., Pestana Lagunas, D., Reyes Garcia, I., Ruiz Perea, A., Ortega Guerrero, A., Marmol Cubillo, M. J., Diaz Munoz, D., Garcia de Castrillon i Ramal, S., Andorra Sunyer, X., Noci Moreno, M. D. L. N., Perez Manrique, R. M., del Campo Molina, E., Martinez Quintana, M. E., Fernandez-Gonzalo, S., Goma Fernandez, G., Navarra-Ventura, G., Baro Serra, A., Fuster, C., Plans Galvan, O., Gil-Castillejos, D., Dalorzo Gonzalez, M., Moran Gallego, F. J., Paredes Borrachero, I., Rodriguez Villamizar, P., Romeu Prieto, J., Sanchez Carretero, M. J., Gallardo Sanchez, S., Bustos Molina, F., Garcia Perez, M. L., Castello-Mora, P., Puig, J., Sanchis-Martin, M. R., Sanchis-Veryser, C. A., Vicente-Fernandez, M. P., Zaragoza, R., Lizama, L., Torres, I., Alvarez, C., Ramirez, P., Martin Cerezuela, M., Montero, M. J., Garcia Cantos, J., Valls, P., Aretxabala Cortajarena, N., Garcia Domelo, P., Gonzalez Cubillo, L., Martin Martinez, M., Perez Francisco, I., Poveda Hernandez, Y., Quintano Rodero, A., Rodriguez Nunez, C., Siegemund, M., Estermann, A., Zellweger, N., Ben Saida, I., Boussarsar, M., Esen, F., Ergin Ozcan, P., Berkey, C., Harb, C., Tandy, M. H., Morgan, E., Shephard, K., Hyzy, R. C., Kenes, M., Nelson, K., Hosse, R. E., Vance, K. M., Austin, C. A., Lerner, A., Sanders, E., Balk, R. A., Bennett, D. A., Vogel, A. R., Chowdhury, L., Devulapally, K., Woodham, M., Cohen, S., Patel, N., Kuza, C. M., Sing, M., Roberson, S., Drumright, K., Sehgal, S., Lahue, S. C., Douglas, V. C., Sarwal, A., Caricato A. (ORCID:0000-0001-5929-120X), Stival E., Valente M., and Serrano A. (ORCID:0000-0002-7622-0101)

Abstract

Background: To date, 750 000 patients with COVID-19 worldwide have required mechanical ventilation and thus are at high risk of acute brain dysfunction (coma and delirium). We aimed to investigate the prevalence of delirium and coma, and risk factors for delirium in critically ill patients with COVID-19, to aid the development of strategies to mitigate delirium and associated sequelae. Methods: This multicentre cohort study included 69 adult intensive care units (ICUs), across 14 countries. We included all patients (aged ≥18 years) admitted to participating ICUs with severe acute respiratory syndrome coronavirus 2 infection before April 28, 2020. Patients who were moribund or had life-support measures withdrawn within 24 h of ICU admission, prisoners, patients with pre-existing mental illness, neurodegenerative disorders, congenital or acquired brain damage, hepatic coma, drug overdose, suicide attempt, or those who were blind or deaf were excluded. We collected de-identified data from electronic health records on patient demographics, delirium and coma assessments, and management strategies for a 21-day period. Additional data on ventilator support, ICU length of stay, and vital status was collected for a 28-day period. The primary outcome was to determine the prevalence of delirium and coma and to investigate any associated risk factors associated with development of delirium the next day. We also investigated predictors of number of days alive without delirium or coma. These outcomes were investigated using multivariable regression. Findings: Between Jan 20 and April 28, 2020, 4530 patients with COVID-19 were admitted to 69 ICUs, of whom 2088 patients were included in the study cohort. The median age of patients was 64 years (IQR 54 to 71) with a median Simplified Acute Physiology Score (SAPS) II of 40·0 (30·0 to 53·0). 1397 (66·9%) of 2088 patients were invasively mechanically ventilated on the day of ICU admission and 1827 (87·5%) were invasively mechanical ven

Published
2021

16. Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up

Author

Martin-Martinez M, Castaneda S, Sanchez-Alonso F, Garcia-Gomez C, Juanatey C, Belmonte-Lopez M, Tornero-Molina J, Santos-Rey J, Sanchez-Gonzalez C, Moreno E, Moreno-Gil M, Cobo-Ibanez T, Pinto-Tasende J, Babio-Herraez J, Bonilla G, Juan-Mas A, Manero-Ruiz F, Romera-Baures M, Bachiller-Corral J, Chamizo-Carmona E, Calvo-Catalan J, Sanmarti R, Erausquin-Arruabarrena C, Garcia-Vicuna R, Barbadillo C, Ros-Exposito S, Turrion A, Gonzalez-Fernandez M, Senabre J, Martinez-Pardo S, Ruibal-Escribano A, Giner-Serret E, Berzosa-Sola E, Martinez-Barrio J, Pagan E, Enriqueta-Peiro M, Bustabad-Reyes S, Erra-Duran A, Alvarez B, Valenciano A, Rivera-Redondo J, Ramos M, Montero S, Morcillo-Valle M, Navio M, Galindo-Izquierdo M, Riera-Soler M, Fiter J, Llorca J, and Gonzalez-Gay M

Published
2020

17. FRI0330 BODY MASS INDEX AND DISEASE ACTIVITY IN CHRONIC INFLAMMATORY RHEUMATIC DISEASES: RESULTS OF THE CARDIOVASCULAR IN RHEUMATOLOGY (CARMA) PROJECT

Author

López-González, R., primary, Valero Jaimes, J. A., additional, Martin-Martinez, M. A., additional, Castañeda, S., additional, García Gomez, C., additional, Sánchez-Alonso, F., additional, Gonzalez Juanatey, C., additional, Revuelta-Evrad, E., additional, Perez-Garcia, C., additional, Torrente Segarra, V., additional, Pérez Sandoval, T., additional, Llorca, J., additional, and González-Gay, M. A., additional

Published
2020
Full Text
View/download PDF

18. OP0002 INCIDENCE OF FIRST CARDIOVASCULAR EVENT IN SPANISH PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: PROSPECTIVE DATA FROM THE CARMA PROJECT AFTER 5 YEARS OF FOLLOW-UP

Author

Martin-Martinez, M. A., primary, Castañeda, S., additional, Sánchez-Alonso, F., additional, García Gomez, C., additional, Gonzalez Juanatey, C., additional, Belmonte, M. A., additional, Tornero, J., additional, Santos Rey, J., additional, Sanchez Gonzalez, C. O., additional, Quesada-Masachs, E., additional, Moreno Gil, M. D., additional, Cobo-Ibáñez, T., additional, Pinto Tasende, J. A., additional, Babío, J., additional, Bonilla, G., additional, Mas, A. J., additional, Manero, J., additional, Romera, M., additional, Bachiller-Corral, J., additional, Chamizo Carmona, E., additional, Calvo, J., additional, Sanmarti, R., additional, Erausquin, M. C., additional, Garcia de Vicuna, R., additional, Barbadillo, C., additional, Ros Exposito, S., additional, Del Pino, J., additional, Gonzalez, M. J., additional, Pina Salvador, J. M., additional, Llorca, J., additional, and González-Gay, M. A., additional

Published
2020
Full Text
View/download PDF

19. AB0428 ASSOCIATION BETWEEN GEOGRAPHIC AND CLIMATOLOGICAL CONDITIONS AND CUTANEOUS MANIFESTATIONS IN LUPUS PATIENTS FROM THE SPANISH RHEUMATOLOGY SOCIETY LUPUS REGISTRY (RELESSER) AND ARGENTINE RHEUMATOLOGY SOCIETY LUPUS REGISTRY (RELESSAR) COHORT

Author

Menor-Almagro, R., primary, Argentina García, M., additional, Rua-Figueroa, I., additional, Pons Estel, G., additional, Martin-Martinez, M. A., additional, Muñoz Jimenez, A., additional, Galindo-Izquierdo, M., additional, Calvo-Alen, J., additional, Fernandez-Nebro, A., additional, Olive, A., additional, Pons-Estel, B., additional, and Pego-Reigosa, J. M., additional

Published
2020
Full Text
View/download PDF

21. HORMONE DEPENDENCE AND CANCER IN SYSTEMIC LUPUS ERYTHEMATOSUS

Author

Cobo-Ibanez T, Urruticoechea-Arana A, Rua-Figueroa I, Martin-Martinez M, Ovalles J, Galindo-Izquierdo M, Calvo-Alen J, Olive A, Fernandez-Nebro A, Menor-Almagro R, Muriel E, Horcada L, Isacelaya E, Taboada V, Andreu J, Boteanu A, Narvaez J, Bohorquez C, Montilla-Morales C, Soler G, Hernandez-Cruz B, Vela-Casasempere P, Perez E, Gonzalez M, Beriain J, Alvarez E, Exposito L, Fernandez-Berrizbeitia O, Marenco J, and Pego-Reigosa J

Published
2019

22. Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA Project

Author

Martin-Martinez, M. A., Castaneda, S., Gonzalez-Juanatey, C., Sanchez-Alonso, F., Garcia-Gomez, C., Lopez-Gonzalez, R., Babio-Herraiz, J., Juan-Mas, A., Moreno-Gil, M. P., Sanchez-Gonzalez, C. O., Romera-Baures, M., Pinto-Tasende, J. A., Tornero-Molina, J., Fabregas-Canales, D., Llorca, J., Gonzalez-Gay, M. A., Gonzalez Rabago, Eugenia, Blanco Morales, Elena Alonso, Fernandez Lopez, J. Carlos, Oreiro Villar, Natividad, Atanes Sandoval, Antonio, Blanco Garcia, Francisco J., Alegre Miquel, Cayetano, Gonzalez Fernandez, Maria J., Huguet Codina, Ramon, Yoldi, Beatriz, Ramentol, Mercedes, Avila, Gabriela, Marsal Barril, Sara, Quesada, Estefania, Steiner, Martina, Munoz, Santiago, Cobo, Tatiana, Gamero, Fernando, Garcia Toron, Jose, Espino, Pilar, Ros, Inmaculada, Ibanez, Monica, Murillo, Claudia, Sanmarti, Raimon, Berman, Horacio, Cabrera, Sonia, Ruiz, Virginia, Fontsere Paton, Oscar, Fernandez Gutierrez, Benjamin, Abasolo, Lydia, Pina, Jose M., Nolla, Joan M., Garcia Arias, Miriam, Garcia Vadillo, Jesus A., Garcia Vicuna, Rosario, Fernandez Nebro, Antonio, Manrique Arija, Sara, Belmonte Lopez, Maria A., Urena, Inmaculada, Irigoyen, Maria V., Coret Cagigal, Virginia, Pielfort Garrido, Daniel, Garcia Aparicio, Angel M., Belmonte Gomez, Rebeca, Granados Bautista, Pastora, Hernandez Sanz, Azucena, Bachiller, Javier, Manero, Francisco J., Jimenez Zorzo, Fernando, Gimenez Ubeda, Eugenio, Marzo Garcia, Jesus, Beltran Audera, Chesus, Medrano, Marta, Pecondon, Angela, Erausquin, Celia, Ojeda, Soledad, Carlos Quevedo, Juan, Francisco, Felix, Rodriguez Lozano, Carlos, Lopez Longo, Francisco J., Gerona, Delia, Gonzalez Fernandez, Carlos, Monteagudo, Indalecio, Del Pino, Javier, Sanchez Gonzalez, Maria Dolores, Corrales, Alfonso, Enriqueta Peiro, Maria, Senabre, Jose M., Rosas, Jose C., Rotes, Isabel, Moreno, Estefania, Erra, Alba, Grado, Dolors, Calvo, Javier, Rueda, Amalia, Moller, Ingrid, Rodriguez, Isabel, Barbadillo, Carmen, Raya, Enrique, Morales, Pilar, Nieto, Ana, Jimenez, Inmaculada, Magro, Cesar, Ruibal Escribano, Ana, Ros Exposito, Sergio, Sanchez Nievas, Gines, Judez Navarro, Enrique, Sianes Fernandez, Manuela, Garcia Morales, Maria A., Labiano Bastero, Isabel, Garcia Consuegra, Gloria, Palmou, Natalia, Martinez Pardo, Silvia, Pujol, Manel, Riera Alonso, Elena, Salvador, Georgina, Gonzalez Alvarez, Beatriz, Cantabrana, Alberto, Bustabad, Sagrario, Delgado, Esmeralda, Alejandro Muñoz-Jiménez, Rodriguez Montero, Sergio, Jimenez, Luis M., Rivera Redondo, Javier, Gonzalez Hernandez, Teresa, Gonzalez Polo, Francisco J., Menor Almagro, Raul, Moreno, Jose M., Giner Serret, Emilio, Lannuzzelli Barroso, Carla, Cebrian Mendez, Laura, Navio, Maria T., Fernandez Carballido, Cristina, Pagan, Encarnacion, Mesa Del Castillo, Pablo, Naredo, Esperanza, Cruz, Ana, Turrion, Ana, Sanchez, Julio, Galindo, Maria, Garcia Gonzalez, Javier, Collantes, Eduardo, Ruiz, Desiree, Font, Pilar, Bonilla, Gema, Lopez Meseguer, Antonio, Moreno, Manuel J., Moreno Martinez, Maria Jose, Beteta Fernandez, Maria D., Linares, Luis F., Morcillo, Mercedes, Gonzalez Gomez, Maria L., Rivera, Natalia A., Fernandez Berrizbeitia, Olaia, Garcia Vivar, Maria L., Riera, Manel, Maria Leon, Yolanda, Maymo, Joan, Amirall, Miriam, Iniesta Escolano, Silvia, Sanchez Serrano, Silvia, Lis Bona, Maria P., Fiter, Jordi, Fernandez Melon, Julia, Espadaler, Luis, Maiz, Olga, Belzunegui, Joaquin, Banegil, Inmaculada, Diaz, Cesar, Valls, Ramon, Castellvi, Ivan, Bonet, Maria, Moreno Ruzafa, Estefania, Calvo Alen, Jaime, Perez Sandoval, Trinidad, Revuelta Evrard, Eva, Godo, Javier R., Fernandez Espartero, Cruz, Navarro Blasco, Francisco J., Gonzalez, Jose A., and Miranda-Filloy, Jose A.

Subjects
rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, incidence, cohort study, CARMA project, cardiovascular diseases
Abstract

Objective To determine the incidence and risk factors of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD). Methods Analysis of data after 2.5 years of follow-up from the prospective study CARMA project, that includes patients with CIRD [rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)] and matched individuals without CIRD from 67 hospitals in Spain. CVE cumulative incidence per 1000 patients was calculated after 2.5 years from the start of the project. Weibull proportional hazard model was used to calculate hazard ratio (HR) and 95% confidence interval (95% CI) of the risk factors. Results 2595 (89.1%) patients completed the 2.5 years of follow-up visit. Cumulative incidence of CVE in patients with CIRD was 15.30 cases per 1000 patients (95% CI: 12.93-17.67), being higher in the subgroup with AS; 22.03 (95% CI: 11.01-33.04). Patients with AS (HR: 4.11; 95% CI: 1.07-15.79), those with older age (HR: 1.09; 95% CI: 1.05-1.13), systolic hypertension (HR: 1.02; 95% CI: 1.00-1.04) and long duration of the disease (HR: 1.07; 95% CI: 1.03-1.12) were at higher risk of first CVE during the 2.5 years of follow-up. In contrast, female gender was a protective factor (HR: 0.43; 95% CI: 0.18-1.00). Conclusion Among CIRD patients prospectively followed-up at rheumatology outpatient clinics, those with AS show higher risk of first CVE. Besides cardiovascular risk factors, such as hypertension, being a man and older

Published
2019

23. Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behcet's Disease: National Multicenter Study of 51 Cases

Author

Atienza-Mateo B, Calderon-Goercke M, Prieto-Pena D, Gonzalez-Mazon I, Sanchez-Bilbao L, Martin-Varillas J, Loricera J, Rio V, Grana J, Espinosa G, Moriano C, Perez-Sandoval T, Martin-Martinez M, Diez E, Garcia-Armario M, Martinez E, Castellvi I, Alvarado P, Sivera F, Calvo-Alen J, de la Morena I, Ortiz-Sanjuan F, Roman-Ivorra J, Perez-Gomez A, Heredia S, Olive-Marques A, Prior-Espanol A, Diez C, Alegre-Sancho J, Ybanez A, Martinez-Ferrer A, Narvaez J, Figeras I, Turrion A, Romero-Yuste S, Trenor P, Ojeda S, Gonzalez-Gay M, and Blanco R

Published
2019

24. Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project

Author

Garcia-Gomez, C, Martin-Martinez, M, Fernandez C, Castaneda, S, Gonzalez-Juanatey, C, Sanchez-Alonso, F, Gonzalez-Fernandez, M, Sanmarti, R, Garcia-Vadillo, J, Fernandez-Gutierrez, B, Garcia-Arias, M, Manero, F, Senabre, J, Rueda-Cid, A, Ros-Exposito, S, Pina-Salvador, J, Erra-Duran, A, Moller-Parera, I, Llorca, J, Gonzalez-Gay, M, Gonzalez de Rabago, E, Blanco Morales, E, Fernandez Lopez, J, Oreiro Villar, N, Atanes Sandoval, A, Blanco Garcia, F, Alegre De Miquel, C, Gonzalez Fernandez, M, Huguet Codina, R, Yoldi, B, Ramentol, M, Avila, G, Marsal Barril, S, Steiner, M, Munoz, S, Gamero, F, Garcia Toron, J, Moreno Gil, M, Mas, A, Espino, P, Ros, I, Ibanez, M, Murillo, C, Piqueras, J, Berman, H, Cabrera, S, Ruiz, V, Fontsere Paton, O, Fernandez Gutierrez, B, Abasolo, L, Fabregas, M, Romera Baures, M, Nolla, J, Gonzalez-Alvaro, I, Tomero Muriel, E, Garcia de Vicuna, R, Fernandez Nebro, A, Belmonte Lopez, M, Urena, I, Irigoyen, M, Coret Cagigal, V, Lopez Gonzalez, R, Pielfort Garrido, D, Sampedro Alvarez, J, Garcia Aparicio, A, Belmonte Gomez, R, Granados Bautista, P, Hernandez Sanz, A, Sanchez Gonzalez, C, Bachiller, J, Zea, A, Jimenez Zorzo, F, Gimenez Ubeda, E, Marzo Gracia, J, Beltran Audera, C, Medrano, M, Pecondon, A, Erausquin, C, Ojeda, S, Carlos Quevedo, J, Francisco, F, Rodriguez Lozano, C, Babio Herraez, J, Lopez Longo, F, Gerona, D, Gonzalez Fernandez, C, Carreno, L, Monteagudo, I, del Pino, J, Sanchez Gonzalez, M, Corrales, A, Enriqueta Peiro, M, Rosas, J, Rotes, I, Moreno, E, Erra, A, Grado, D, Calvo, J, Rueda, A, Moller, I, Rodriguez, I, Barbadillo, C, Raya, E, Morales, P, Nieto, A, Jimenez, I, Magro, C, Ruibal Escribano, A, Ros Exposito, S, Sanchez Nievas, G, Judez Navarro, E, Sianes Fernandez, M, Garcia Morales, M, Labiano Bastero, I, Consuegra, G, Palmou, N, Martinez Pardo, S, Pujol, M, Riera Alonso, E, Salvador, G, Gonzalez Alvarez, B, Cantabrana, A, Bustabad, S, Delgado, E, Munoz, A, Rodriguez Montero, S, Maria Jimenez, L, Rivera Redondo, J, Gonzalez Hernandez, T, Gonzalez Polo, F, Menor Almagro, R, Moreno, J, Giner Serret, E, Lannuzzelli Barroso, C, Cebrian Mendez, L, Teresa Navio, M, Fernandez Carballido, C, Pagan, E, Mesa del Castillo, P, Naredo, E, Cruz, A, Turrion, A, Mateo, I, Sanchez, J, Galindo, M, Garcia Gonzalez, J, Collantes, E, Ruiz, D, Font, P, Bonilla, G, Lopez Meseguer, A, Moreno, M, Moreno Martinez, M, Beteta Fernandez, M, Linares, L, Morcillo, M, Gonzalez Gomez, M, Aramburu, J, Rivera, N, Fernandez Berrizbeitia, O, Garcia Vivar, M, Riera, M, Maria Leon, Y, Maymo, J, Amirall, M, Iniesta Escolano, S, Sanchez Serrano, S, Lis Bona, M, Fiter, J, Fernandez Melon, J, Espadaler, L, Maiz, O, Belzunegui, J, Banegil, I, Diaz, C, Valls, R, Castellvi, I, Bonet, M, Moreno Ruzafa, E, Calvo Alen, J, Perez Sandoval, T, Revuelta Evrard, E, Godo, J, Fernandez Espartero, C, Navarro Blasco, F, Antonio Gonzalez, J, Miranda-Filloy, J, and CARMA Project Collaborative Grp

Subjects
musculoskeletal diseases, psoriatic arthritis, lipids, stomatognathic diseases, cardiovascular disease, lipoprotein(a), ankylosing spondylitis, spondyloarthritis
Abstract

Objective Cardiovascular (CV) disease is one of the main causes of morbi-mortality in spondyloarthritis (SpA), partially explained by traditional CV risk factors. Information on lipoprotein(a) [Lp(a)], a non-conventional risk factor, in SpA is scarce. In this study we assessed the prevalence of hyperlipoproteinaemia(a) in SpA patients and analysed the possible related factors. Methods A baseline analysis was made of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and controls included in the CARMA project (CARdiovascular in RheuMAtology), a 10-year prospective study evaluating the risk of CV events in chronic inflammatory rheumatic diseases. A multivariate logistic regression model was performed using hyperlipoproteinaemia( a) (Lp(a) >50 mg/dl) as a dependent variable and adjusting for confounding factors. Results 19.2% (95% CI: 16.80-22.05) of the SpA patients [20.7% (95% CI: 16.91-24.82) of those with AS and 17.7% (95% CI: 14.15-21.75) of those with PsA] and 16.7% (95% CI: 13.23-20.86) of the controls had hyperlipoproteinaemia(a) (p=0.326). Adjusting for age and sex, SpA patients were more likely to have hyperlipoproteinaemia(a) than controls (OR: 1.43, 95% CI: 1.00-2.04; p=0.05), especially those with AS (OR: 1.81, 95% CI: 1.18-2.77; p=0.007). In the adjusted model, apolipoprotein B in all patients, non-steroidal anti-inflammatory drugs in AS, and female sex in PsA, were associated with hyperlipoproteinaemia(a). No disease-specific factors associated with hyperlipoproteinaemia(a) were identified. Conclusion SpA patients show a moderately increased risk of hyperlipoproteinaemia(a) compared to controls, especially those with AS. Lp(a) determination may be of interest to improve the CV risk assessment in SpA patients.

Published
2019

37. Conformationally Constrained CCK4 Analogues Incorporating IBTM and BTD β-Turn Mimetics

Author

Martin-Martinez, M., Figuera, N. De la, LaTorre, M., Garcia-Lopez, M. T., Cenarruzabeitia, E., Rio, J. Del, and Gonzalez-Muniz, R.

Abstract

To test whether a turnlike arrangement is involved in the bioactive conformation of CCK4 analogues upon CCK1 receptor recognition, we describe the preparation of two series of CCK4 derivatives, in which the central dipeptide Met-Asp has been replaced by recognized β-turn mimetics {(2S,5S,11bR)- and (2R,5R,11bS)-2-amino-5-carboxy-3-oxo-2,3,5,6,11,11b-hexahydro-1H-indolizino[8,7-b]indole (IBTM) and β-turn dipeptide, 2-oxo-7-thio-1-azabicyclo[4.3.0]nonane (BTD)}. The incorporation of the indolizinoindole IBTM type II β-turn mimetic is preferred over its type II‘ counterpart for efficient CCK1 receptor recognition, while BTD derivatives were completely inactive. The structure−conformation−activity relationship study in the IBTM series has shown some essential requirement of these CCK4 derivatives to favorably interact with CCK1 receptors:  (a) the adoption of turnlike conformations, (b) the presence of an l-Phe residue and a C-terminal carboxamide moiety, and (c) the indole ring of the IBTM skeleton. Moreover, the existence of π−π interactions between the phenyl ring of d-Phe residues and the indole ring of IBTM framework is detrimental for binding affinity. A series of potent and selective CCK1 receptor antagonists, exemplified by compounds 8a and 8b, emerges among these IBTM-containing derivatives.

Published
2005

38. Combination of Molecular Modeling, Site-Directed Mutagenesis, and SAR Studies To Delineate the Binding Site of Pyridopyrimidine Antagonists on the Human CCK1 Receptor

Author

Martin-Martinez, M., Marty, A., Jourdan, M., Escrieut, C., Archer, E., Gonzalez-Muniz, R., Garcia-Lopez, M. T., Maigret, B., Herranz, R., and Fourmy, D.

Abstract

A rational combination of site-directed mutagenesis studies, structure−activity relationships, and dynamic-based docking of pyridopyrimidine-derived CCK1R antagonists into a refined three-dimensional model of the CCK1R allowed us to identify the receptor residues and the ligand functional groups implicated in the molecular recognition process. Our results provided unambiguous evidence that the binding site of these antagonists is overlapping that of the C-terminal tetrapeptide of CCK. In particular, Asn333 and Arg336 residues of the CCK1R are essential for high-affinity binding of these ligands. Moreover, the 2-aryl group in the pyridopyrimidine derivatives shares the same binding pocket as the C-terminal Phe side chain of CCK. Our [pyridopyrimidine·CCK1R] complex model is consistent with previous suggestions concerning the molecular basis that governs functional activity and provides useful considerations about the high CCK1 versus CCK2 selectivity of our derivatives and could contribute to fine-tune the rational design of new molecules with optimized properties.

Published
2005

39. Synthesis, Conformational Analysis, and Cytotoxicity of Conformationally Constrained Aplidine and Tamandarin A Analogues Incorporating a Spirolactam β-Turn Mimetic

Author

Gutierrez-Rodriguez, M., Martin-Martinez, M., Garcia-Lopez, M. T., Herranz, R., Cuevas, F., Polanco, C., Rodriguez-Campos, I., Manzanares, I., Cardenas, F., Feliz, M., Lloyd-Williams, P., and Giralt, E.

Abstract

With the aim of studying the contribution of the β II turn conformation at the side chain of didemnins to the bioactive conformation responsible for their antitumoral activity, conformationally restricted analogues of aplidine and tamandarin A, where the side chain dipeptide Pro8-N-Me-d-Leu7 is replaced with the spirolactam β II turn mimetic (5R)-7-[(1R)-1-carbonyl-3-methylbutyl]-6-oxo-1,7-diazaspiro[4.4]nonane, were prepared. Additionally, restricted analogues, where the aplidine (pyruvyl9) or tamandarin A [(S)-Lac9] acyl groups are replaced with the isobutyryl, Boc, and 2-methylacryloyl groups, were also prepared. These structural modifications were detrimental to cytotoxic activity, leading to a decrease of 1−2 orders of magnitude with respect to that exhibited by aplidine and tamandarin A. The conformational analysis of one of these spirolactam aplidine analogues, by NMR and molecular modeling methods, showed that the conformational restriction caused by the spirolactam does not produce significant changes in the overall conformation of aplidine, apart from preferentially stabilizing the trans rotamer at the pyruvyl9−spirolactam amide bond, whereas in aplidine both cis and trans rotamers at the pyruvyl9−Pro8 amide bond are more or less equally stabilized. These results seem to indicate a preference for the cis form at that amide bond in the bioactive conformation of aplidine. The significant influence of this cis/trans isomerism upon the cytotoxicity suggests a possible participation of a peptidylprolyl cis/trans isomerase in the mechanism of action of aplidine.

Published
2004

41. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-Based Potent and Selective CCK<INF>1</INF> Receptor Antagonists:  Structure−Activity Relationship Studies on the Substituent at N2-Position

Author

Bartolome-Nebreda, J. M., Patino-Molina, R., Martin-Martinez, M., Gomez-Monterrey, I., Garcia-Lopez, M. T., Gonzalez-Muniz, R., Cenarruzabeitia, E., Latorre, M., Rio, J. D., and Herranz, R.

Abstract

To establish structure−activity relationships a new series of analogues of the highly potent and selective CCK1 receptor antagonist (4aS,5R)-2-benzyl-5-(N-Boc-tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]-pyrimidine (1a) modified at N2-position of the central scaffold has been prepared and evaluated as CCK receptor ligands. With this aim the N2-benzyl group has been replaced by methyl, cyclohexyl, aromatic groups, 1-phenylethyl, and 1-carboxy-2-phenylethyl group. Then, substituents with different electronic and steric properties were introduced into different positions of the phenyl group of analogues 19a and 19b. The results of the CCK receptor binding and in vitro functional activity evaluation suggest the importance of the lipophilic character and an appropriate spatial orientation of the moiety linked at the N2-position of the 1,3-dioxoperhydropyrido[1,2-c]pyrimidine template for potent and selective binding and antagonist activity at CCK1 receptor subtype. The 2-cyclohexyl and (2S)-1-naphthyl derivatives 18a and (2S)-20a have emerged as more potent and selective CCK1 receptor antagonists than the lead compound 1a. Additionally, the results confirm the (4aS,5R)-stereochemistry at the central bicyclic skeleton as an essential structural requirement for potent binding to this receptor subtype.

Published
2001

44. β-Turned Dipeptoids as Potent and Selective CCK<INF>1</INF> Receptor Antagonists

Author

Martin-Martinez, M., Figuera, N. De la, Latorre, M., Herranz, R., Garcia-Lopez, M. T., Cenarruzabeitia, E., Rio, J. Del, and Gonzalez-Muniz, R.

Abstract

To improve our knowledge of the bioactive conformation of CCK1 antagonists, we previously described that replacement of the α-MeTrp residue of dipeptoids with the (2S,5S,11bR)-2-amino-3-oxohexahydroindolizino[8,7-b]indole-5-carboxylate (IBTM) skeleton, a probed type II‘ β-turn mimetic, led to restricted analogues (2S,5S,11bR,1‘S)- and (2S,5S,11bR,1‘R)-2-(benzyloxycarbonyl)amino-5-[1‘-benzyl-2‘-(carboxy)ethyl]carbamoyl-3-oxo-2,3,5,6,11,11b-hexahydro-1H-indolizino[8,7-b]indole, 1a,b, showing high binding affinity and selectivity for CCK1 receptors. In this report, we describe the synthesis and binding profile of new analogues of compounds 1 designed to explore the importance of the C-terminal residue and of the type of β-turn on the receptor binding affinity and selectivity. Structure−affinity relationship studies show that a C-terminal free carboxylic acid and an S configuration of the Phe and βHph residues are favorable for CCK1 receptor recognition. Moreover, selectivity for this receptor subtype is critically affected by the β-turn type. Thus, while compounds 15a and 16a, containing the (2S,5S,11bR)- and (2R,5R,11bS)-IBTM frameworks, respectively, are both endowed with nanomolar affinity for CCK1 receptors, restricted dipeptoid derivative 15a, incorporating the type II‘ IBTM mimetic, shows approximately 6-fold higher CCK1 selectivity than analogue 16a, with the type II mimetic. From these results, we propose that the presence of a β-turn-like conformation within the peptide backbone of dipeptoids could contribute to their bioactive conformation at the CCK1 receptor subtype. Concerning functional activity, compounds 15a and 16a behave as CCK1 receptor antagonists.

Published
2000

45. 5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-Based Potent and Selective CCK<INF>1</INF> Receptor Antagonists:  Structural Modifications at the Tryptophan Domain

Author

Bartolome-Nebreda, J. M., Gomez-Monterrey, I., Garcia-Lopez, M. T., Gonzalez-Muniz, R., Martin-Martinez, M., Ballaz, S., Cenarruzabeitia, E., LaTorre, M., Rio, J. Del, and Herranz, R.

Abstract

Analogues of the previously reported potent and highly selective CCK1 receptor antagonist (4aS,5R)-2-benzyl-5-(N-Boc-tryptophyl)amino-1,3-dioxoperhydropyrido-[1,2-c]pyrimidine (2a) were prepared to explore the structural requirements at the Boc-tryptophan domain for CCK1 receptor affinity. Structural modifications of 2a involved the Trp side chain, its conformational freedom, the Boc group, and the carboxamide bond. Results of the CCK binding and in vitro functional activity evaluation showed three highly strict structural requirements:  the type and orientation of the Trp side chain, the H-bonding acceptor carbonyl group of the carboxamide bond, and the presence of the Trp amino protection Boc. Replacement of this acid-labile group with 3,3-dimethylbutyryl or tert-butylaminocarbonyl conferred acid stability to analogues 14a and 15a, which retained a high potency and selectivity in binding to CCK1 receptors, as well as an in vivo antagonist activity against the acute pancreatitis induced by caerulein in rats. Oral administration of compounds 14a and 15a also produced a lasting antagonism to the hypomotility induced by CCK-8 in mice, suggesting a good bioavailability and metabolic stability.

Published
1999

47. Synthesis and Stereochemical Structure−Activity Relationships of 1,3-Dioxoperhydropyrido[1,2-c]pyrimidine Derivatives:  Potent and Selective Cholecystokinin-A Receptor Antagonists

Author

Martin-Martinez, M., Bartolome-Nebreda, J. M., Gomez-Monterrey, I., Gonzalez-Muniz, R., Garcia-Lopez, M. T., Ballaz, S., Barber, A., Fortuno, A., Rio, J. Del, and Herranz, R.

Abstract

The synthesis and stereochemical structure−activity relationships of a new class of potent and selective non-peptide cholecystokinin-A (CCK-A) receptor antagonists based on the 1,3-dioxoperhydropyrido[1,2-c]pyrimidine skeleton are described. The most potent member of this series of eight diastereoisomers, (4aS,5R)-2-benzyl-5-[N-[(tert-butoxycarbonyl)-l-tryptophyl]amino]-1,3-dioxoperhydropyrido[1,2-c]pyrimidine, displays nanomolar CCK-A receptor affinity and higher than 8000-fold potency at the CCK-A than at the CCK-B receptor. As CCK-A antagonist, this compound inhibits the CCK-8-evoked amylase release from pancreatic acinar cells at a low concentration, similar to that of the typical antagonist Devazepide. Highly strict stereochemical requirements for CCK-A receptor binding and selectivity have been found. The l-Trp and the 4a,5-trans disposition of the bicyclic perhydropyrido[1,2-c]pyrimidine are essential for binding potency and selectivity.

Published
1997

50. Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project

Author

Garcia-Gomez, C., Martin-Martinez, M. A., Fernandez-Carballido, C., Castaneda, S., Gonzalez-Juanatey, C., Sanchez-Alonso, F., Gonzalez-Fernandez, M. J., Sanmarti, R., Garcia-Vadillo, J. A., Fernandez-Gutierrez, B., Garcia-Arias, M., Manero, F. J., Senabre, J. M., Rueda-Cid, A., Ros-Exposito, S., Pina-Salvador, J. M., Erra-Duran, A., Moller-Parera, I., Llorca, J., Gonzalez-Gay, M. A., Gonzalez Rabago, Eugenia, Blanco Morales, Elena Alonso, Fernandez Lopez, J. Carlos, Oreiro Villar, Natividad, Atanes Sandoval, Antonio, Blanco Garcia, Francisco J., Alegre Miquel, Cayetano, Gonzalez Fernandez, Maria J., Huguet Codina, Ramon, Yoldi, Beatriz, Ramentol, Mercedes, Avila, Gabriela, Marsal Barril, Sara, Steiner, Martina, Munoz, Santiago, Gamero, Fernando, Garcia Toron, Jose, Moreno Gil, Maria P., Mas, Antonio J., Espino, Pilar, Ros, Inmaculada, Ibanez, Monica, Murillo, Claudia, Piqueras, Jose A., Sanmarti, Raimon, Berman, Horacio, Cabrera, Sonia, Ruiz, Virginia, Fontsere Paton, Oscar, Fernandez Gutierrez, Benjamin, Abasolo, Lydia, Fabregas, Maria D., Romera Baures, Montserrat, Nolla, Joan M., Gonzalez-Alvaro, Isidoro, Tomero Muriel, Eva G., Garcia Vicuna, Rosario, Fernandez Nebro, Antonio, Belmonte Lopez, Maria Angeles, Urena, Inmaculada, Irigoyen, Maria V., Coret Cagigal, Virginia, Lopez Gonzalez, Ruth, Pielfort Garrido, Daniel, Sampedro Alvarez, Juana, Garcia Aparicio, Angel Maria, Belmonte Gomez, Rebeca, Granados Bautista, Pastora, Hernandez Sanz, Azucena, Sanchez Gonzalez, Carmen O., Bachiller, Javier, Zea, Antonio, Manero, Francisco J., Jimenez Zorzo, Fernando, Gimenez Ubeda, Eugenio, Marzo Gracia, Jesus, Beltran Audera, Chesus, Medrano, Marta, Pecondon, Angela, Erausquin, Celia, Ojeda, Soledad, Carlos Quevedo, Juan, Francisco, Felix, Rodriguez Lozano, Carlos, Babio Herraez, Jesus, Lopez Longo, Francisco J., Gerona, Delia, Gonzalez Fernandez, Carlos, Carreno, Luis, Monteagudo, Indalecio, Del Pino, Javier, Sanchez Gonzalez, Maria Dolores, Corrales, Alfonso, Enriqueta Peiro, Maria, Senabre, Jose M., Rosas, Jose C., Rotes, Isabel, Moreno, Estefania, Erra, Alba, Grado, Dolors, Calvo, Javier, Rueda, Amalia, Moller, Ingrid, Rodriguez, Isabel, Barbadillo, Carmen, Raya, Enrique, Morales, Pilar, Nieto, Ana, Jimenez, Inmaculada, Magro, Cesar, Ruibal Escribano, Ana, Ros Exposito, Sergio, Sanchez Nievas, Gines, Judez Navarro, Enrique, Sianes Fernandez, Manuela, Garcia Morales, Maria Angeles, Labiano Bastero, Isabel, Consuegra, Gloria, Palmou, Natalia, Martinez Pardo, Silvia, Pujol, Manel, Riera Alonso, Elena, Salvador, Georgina, Gonzalez Alvarez, Beatriz, Cantabrana, Alberto, Bustabad, Sagrario, Delgado, Esmeralda, Alejandro Muñoz-Jiménez, Rodriguez Montero, Sergio, Maria Jimenez, Luis, Rivera Redondo, Javier, Gonzalez Hernandez, Teresa, Gonzalez Polo, Francisco J., Menor Almagro, Raul, Moreno, Jose M., Giner Serret, Emilio, Lannuzzelli Barroso, Carla, Cebrian Mendez, Laura, Teresa Navio, Maria, Fernandez Carballido, Cristina, Pagan, Encarnacion, Mesa Del Castillo, Pablo, Naredo, Esperanza, Cruz, Ana, Turrion, Ana, Mateo, Isabel, Sanchez, Julio, Galindo, Maria, Garcia Gonzalez, Javier, Collantes, Eduardo, Ruiz, Desiree, Font, Pilar, Bonilla, Gema, Lopez Meseguer, Antonio, Moreno, Manuel J., Moreno Martinez, Ma Jose, Beteta Fernandez, Ma Dolores, Linares, Luis F., Morcillo, Mercedes, Gonzalez Gomez, Maria L., Aramburu, Jose M., Rivera, Natalia A., Fernandez Berrizbeitia, Olaia, Garcia Vivar, Maria Luz, Riera, Manel, Maria Leon, Yolanda, Maymo, Joan, Amirall, Miriam, Iniesta Escolano, Silvia, Sanchez Serrano, Silvia, Lis Bona, Maria Pilar, Fiter, Jordi, Fernandez Melon, Julia, Espadaler, Luis, Maiz, Olga, Belzunegui, Joaquin, Banegil, Inmaculada, Diaz, Cesar, Valls, Ramon, Castellvi, Ivan, Bonet, Maria, Moreno Ruzafa, Estefania, Calvo Alen, Jaime, Perez Sandoval, Trinidad, Revuelta Evrard, Eva, Godo, Javier R., Fernandez Espartero, Cruz, Navarro Blasco, Francisco J., Antonio Gonzalez, Jose, and Miranda-Filloy, Jose A.

Subjects
psoriatic arthritis, lipids, cardiovascular disease, lipoprotein(a), ankylosing spondylitis, spondyloarthritis
Abstract

Objective Cardiovascular (CV) disease is one of the main causes of morbi-mortality in spondyloarthritis (SpA), partially explained by traditional CV risk factors. Information on lipoprotein(a) [Lp(a)], a non-conventional risk factor, in SpA is scarce. In this study we assessed the prevalence of hyperlipoproteinaemia(a) in SpA patients and analysed the possible related factors. Methods A baseline analysis was made of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and controls included in the CARMA project (CARdiovascular in RheuMAtology), a 10-year prospective study evaluating the risk of CV events in chronic inflammatory rheumatic diseases. A multivariate logistic regression model was performed using hyperlipoproteinaemia( a) (Lp(a) >50 mg/dl) as a dependent variable and adjusting for confounding factors. Results 19.2% (95% CI: 16.80-22.05) of the SpA patients [20.7% (95% CI: 16.91-24.82) of those with AS and 17.7% (95% CI: 14.15-21.75) of those with PsA] and 16.7% (95% CI: 13.23-20.86) of the controls had hyperlipoproteinaemia(a) (p=0.326). Adjusting for age and sex, SpA patients were more likely to have hyperlipoproteinaemia(a) than controls (OR: 1.43, 95% CI: 1.00-2.04; p=0.05), especially those with AS (OR: 1.81, 95% CI: 1.18-2.77; p=0.007). In the adjusted model, apolipoprotein B in all patients, non-steroidal anti-inflammatory drugs in AS, and female sex in PsA, were associated with hyperlipoproteinaemia(a). No disease-specific factors associated with hyperlipoproteinaemia(a) were identified. Conclusion SpA patients show a moderately increased risk of hyperlipoproteinaemia(a) compared to controls, especially those with AS. Lp(a) determination may be of interest to improve the CV risk assessment in SpA patients.

Catalog

Books, media, physical & digital resources
See catalog results